Kornimate/medical-research-clean huggingface dataset:
compare the renal protective effects of febuxostat and benzbromarone in ckd chinese patients

Conditions: Chronic Kidney Disease; Hyperuricemia; Abnormal Renal Function

Summary: the purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

chronic kidney disease patients with hyperuricemia and glomerular filtration rate (gfr) 20-60 ml/min were treated by febuxostat or benzbromarone. follow up the changes of serum uric acid, serum creatinine and gfr levels. compare the effects on renal function of these two drugs.

Eligibility criteria:
inclusion criteria: chronic kidney disease patients with glomerular filtration rate (gfr,20-60ml/min) who match one of the following criteria: 1. gout 2. serum uric acid \> 480umol/l exclusion criteria: 1. gfr\ 60ml/min 2. liver dysfunction (aspartate transaminase or/and alanine aminotransferase exceed 2 times of normal range) 3. urinary tract obstruction 4. unstable angina, heart failure (stage iii-iv, nyha), new stroke, need diuretics for long-term treatment 5. severe lung diseases or cancers 6. pregnant woman or woman who prepare to be pregnant，nursing mothers 7. unable to sign informed consent form，or disagree with following-up

Keywords: hyperuricemia renal function chronic kidney disease febuxostat benzbromarone
benson relaxation technique and stress in pregnancy

Conditions: Anxiety; Stress; Relation, Interpersonal

Summary: the aim of this study is to determine the effect of the benson relaxation technique applied to pregnant women on their fear of birth, anxiety and stress levels.

the aim of this study is to determine the effect of the benson relaxation technique applied to pregnant women on their fear of birth, anxiety and stress levels. hypotheses ; h0-1: benson relaxation technique applied to pregnant women has an effect on childbirth. h1-1: benson relaxation technique applied to pregnant women has no effect on childbirth. h0-2: benson relaxation technique applied to pregnant women has no effect on anxiety. h1-2: benson relaxation technique applied to pregnant women has an effect on anxiety. h0-3: benson relaxation technique applied to pregnant women and their partners has no effect on stress. h1-3: benson relaxation technique applied to pregnant women and their partners has an effect on stress the study will be conducted on two different groups. the application will be a 1-hour benson relaxation technique applied to pregnant women in the third trimester every week for 4 weeks. participants will be asked to do relaxation exercises twice a day, morning and evening, for 10 to 15 minutes for 1 month. a phone number that patients can call with questions will also be provided. in addition, the researcher will call the women in the intervention group every week to follow up on the relaxation process and answer questions. after the women are evaluated in terms of eligibility criteria for the study, information about the study will be provided to the women who are eligible and written informed consent will be obtained from the women who accept. the random distribution of the women to the study groups will be carried out using the block randomization method. the following applications will be applied to the groups. the researcher will contact the experimental group by phone. the application will end after 4 weeks.

Eligibility criteria:
inclusion criteria: * those who are in their 28th-38th weeks of pregnancy, * people with mental illness, * people who have anxiety disorder, * people with hearing loss; * people who have no experience of using relaxation methods in the past, * people who have not used herbal or medical sedatives exclusion criteria: * those who do not want to participate in the intervention, * those who have a termination of pregnancy during the intervention, * those who have a risky pregnancy
effects of oral care with glutamine on oral health, oral flora and incidence of pneumonia after neurosurgery with microbiome analysis

Conditions: Oral Mucositis; Pneumonia

Summary: a randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total knee arthroplasty.

a randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total knee arthroplasty. subjects will be monitored for occurrence of any complications, particularly deep venous thrombosis and thromboembolism during the hospital stay and for 1 months postoperatively

Eligibility criteria:
inclusion criteria: * adult patients who plan to undergo simultaneous primary total knee arthroplasty on bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis; * all patients who have normal preoperative platelet count, normal prothrombin time, normal partial thromboplastin time, and normal international normalized ratio; * the use of only balanced electrolyte solutions and/or albumin for plasma volume restitution. exclusion criteria: * allergy to tranexamic acid; * receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis, pulmonary embolism, or renal impairment; or were pregnant; * patients with any cardiovascular problems (such as myocardiac infarction history, atrial fibrillation, angina); * patients with thromboembolic disorders, or those exhibiting a deteriorating general condition; * preoperative anemia (a hemoglobin value of \<11 g/dl in females and \<12 g/dl in males), refusal of blood products; * preoperative use of anticoagulant therapy within five days before surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment, coagulopathy (as identified by a preoperative platelet count of \ 1.4, or a prolonged partial thromboplastin time \[\>1.4 times normal\]).
safety and efficacy of buprenorphine transdermal system (btds) in subjects with moderate to severe low back pain

Conditions: Back Pain Lower Back Chronic

Summary: the objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (btds) 20 in comparison to the buprenorphine transdermal system (btds) 5 and oxycodone immediate-release in subjects with moderate to severe low back pain currently treated with oral opioids. the double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will be provided to all subjects in addition to study drug.

buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Eligibility criteria:
inclusion criteria: * low back pain for 3 months or longer, confirmed by radiographic evidence. * receiving a stable dose of an opioid analgesic for low back pain. exclusion criteria: * taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment. * requiring frequent analgesic therapy for chronic condition(s), in addition to low back pain. other protocol-specific exclusion/inclusion criteria may apply.

Keywords: low back pain opioid transdermal butrans
short term effect of empagliflozin in hypertension

Conditions: Hypertension

Summary: the investigators assessed the 6-week effect of once daily 25mg sglt2-i empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

background: the rapid beneficial effects of empagliflozin on cardiovascular mortality and hospitalizations rates for heart failure according to the cardiovascular outcome event trial in type 2 diabetes mellitus patients (empa-reg outcome) trial raise some question in the mechanism of myocardial action. the investigators conducted this study in a population of non-diabetic hypertensive patients in order to look for a short-term effect on left ventricular relaxation. methods: the investigators carried out a single arm non- randomized clinical trial and assigned patients to receive 25mg of empagliflozin once daily in additional therapy for six weeks at the national center for obesity and in the cardiology department of yaounde central hospital in hypertensive patients with cardiac relaxation disorder. the objectives were to evaluate the left ventricular diastolic function and nycthemeral blood pressure profile.

Eligibility criteria:
inclusion criteria: * grade 1 hypertension * grade 1 or 2 relaxation abnormalities (doppler e/a ratio \<1) * unchanged antihypertensive treatment for at least 12 weeks exclusion criteria: * diabetes mellitus * egfr \< 60 ml/min/1,73 m² * mitral stenosis * atrial fibrillation * alanine transferase above 2n

Keywords: hypertension empagliflozin left ventricular diastolic function blood pressure
safety and efficacy of inhaled iloprost in pediatric patients with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to evaluate the safety and effectiveness of iloprost for pah in children who are between the ages of 3 and 18 years old.


Eligibility criteria:
inclusion criteria: * male or female, age 3-18 years * diagnosis of pah due to ipah, connective tissue disease, or congenital heart disease * pulmonary arterial hypertension confirmed by a cardiac catheterization, with mpap \> 25 mmhg at rest, pcwp or lvedp ≤ 15 mmhg, and pvr ≥ 240 dynes/sec/cm-5 (ie, ≥ 3.0 units m2) * nyha/who functional class ii, iii, or iv * have had a 6-minute walk test (6-mwt) performed within the 3 months preceding the screening visit (if ≥ 8 years of age) * have had cardiopulmonary exercise testing (cpet) performed within the 3 months preceding the screening visit (if ≥ 8 years of age and \> 130 cms in height. cpet testing will be conducted on nyha/who class iv patients at the discretion of the principal investigator) * if receiving therapy for pah, on a stable dose and regimen for at least 3 months prior to the screening visit * if receiving digoxin, diuretic, or oxygen therapy, on a stable dose and regimen for at least 30 days preceding the screening visit * must demonstrate the ability to appropriately use the nebulizer device as part of the screening process exclusion criteria: * prior use of prostacyclins or prostacyclin analogues within 3 months prior to screening * portal hypertension or clinically relevant hepatic disease * eisenmenger syndrome with resting spo2 \<88% on room air * clinically relevant asthma or other chronic lung disease, such as bronchopulmonary dysplasia, cystic fibrosis, or repaired or unrepaired congenital diaphragmatic hernia * diagnosis or current evidence of active lung infection or clinically relevant hemoptysis * left-sided heart disease, including valvular disease or heart failure * initiation or dosage adjustment of pah-specific therapy within 3 months prior to screening * initiation of treatment with digoxin, diuretics, anticoagulation, or oxygen therapy within 30 days prior to screening

Keywords: pah pediatric pulmonary arterial hypertension
late-lumen changes after drug-coated balloon angioplasty versus drug-eluting stents in de novo coronary lesions

Conditions: Coronary Artery Disease

Summary: this study aims to compare late-lumen loss (lll) between dcb and des to treat de novo coronary artery stenosis by intravascular ultrasound (ivus).

drug-eluting stent (des) is the standard of care for patients with coronary artery disease who are eligible for percutaneous coronary intervention (pci).1 during long-term follow-up, remained metallic stent strut continuously related with stent-related cardiovascular events.2 as an alternative option to des, drug-coated balloon (dcb) which has benefit of having shorter dapt maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. based on meta-analysis based on many randomized clinical trials (rct),3,4 its use has been established in in-stent restenosis of bare-metal stents and des.5 furthermore, recent rcts demonstrated efficacy and safety of dcb in de novo coronary lesions in small vessels with reference vessel size \<3.0mm.6,7 for the patients with de novo, non-complex coronary artery lesions, rec-cagefree i tested the non-inferiority of dcb angioplasty with des implantation, irrespective of vessel diameter.8 overall, 2272 patients were randomly assigned to the dcb or the des group. at 2 years, adverse events occurred in 6.4% of dcb group and 3.4% of des group and failed to prove the non-inferiority of dcb angioplasty (p for non-inferiority=0.65). regarding the heterogenous results, it is questionable that dcb angioplasty for large de novo lesions is safe and effective compared with des implantation. on this background, the current study aims to compare late-lumen loss (lll) between dcb and des to treat de novo coronary artery stenosis by intravascular ultrasound (ivus).

Eligibility criteria:
inclusion criteria 1. subject must be at least 19 years of age 2. subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily 3. patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥3.0 mm exclusion criteria 1. patients unable to provide consent 2. patients with known intolerance to aspirin, p2y12 inhibitors, or components of drug-eluting stents 3. patients with angiographic findings of 1) left main coronary artery disease 2) in-stent restenosis is the cause of target lesion 3) target lesion in bypass graft 4) true bifurcation lesion that requires upfront 2-stenting 4. patients who have non-cardiac co-morbid conditions with life expectancy \<1 year 5. patients who may result in protocol non-compliance (site investigator's medical judgment) 6. patients with cardiogenic shock or cardiac arrest 7. patients with severe left ventricular systolic dysfunction (ejection fraction \<30%) 8. patients with severe valvular heart disease requiring open heart surgery 9. pregnant or lactating women

Keywords: drug-coated balloon intravascular ultrasound
an investigational study of bg-89894 tablets in participants with advanced solid tumors

Conditions: Advanced or Metastatic MTAP-deleted Solid Tumors

Summary: this study is being done to learn more about a new drug called bg-89894 (previously known as syh2039). researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. the information gathered may help guide how future studies are designed. the entire study is expected to last about four years. people who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. the study plans to enroll participants over a three-year period.


Eligibility criteria:
key inclusion criteria: * must sign a written informed consent and willing to comply with all study-related procedures and requirements. * age ≥18 years (or the legal age of consent according to local regulations). * histologically or cytologically confirmed diagnosis of advanced, metastatic, or unresectable solid tumors that have progressed on or after standard therapy, or for which no appropriate standard therapy is available. * evidence of methylthioadenosine phosphorylase (mtap) homozygous deletion or loss of mtap expression in tumor tissue. * participants must be able to provide an archived tumor tissue sample or unstained fresh biopsy if there is no archival tissue at baseline. * eastern cooperative oncology group (ecog) performance status of 0 or 1 and evidence of adequate organ function and bone marrow reserve, as defined in the study protocol. key exclusion criteria: * history of other malignancies or concurrent active malignancies within 3 years. * prior treatment with methionine adenosyltransferase 2 alpha (mat2a) inhibitors (e.g., ag-270, ide397) or methylthioadenosine (mta)-cooperative protein arginine methyltransferase 5 (prmt5) inhibitors (e.g., amg193). * uncontrolled or active central nervous system (cns) disease, including untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal carcinomatosis. * active bleeding, history of major bleeding events within the past 6 months, or tumors associated with a high risk of vascular invasion. * receipt of systemic anticancer therapy, radiation therapy, live vaccine, or major surgical procedures within protocol-specified washout periods. * active or uncontrolled infections, including tuberculosis (tb), (covid-19, known human immunodeficiency virus (hiv) infection, or uncontrolled hepatitis b virus (hbv) infection. note: additional eligibility criteria may apply.
time gain in the diagnosis myocardial infarction by troponin point of care testing in the emergency room

Conditions: Non STEMI; Angina Pectoris; Angina, Stable; Angina, Unstable; Angina, Prinzmetal's

Summary: the investigators prospectively want to compare 3 clinical tests for measuring blood troponin levels in patients presenting to the emergency room with thoracic pain probably related to a myocardial infarction with regard to the time necessary to obtain the test results. the tests are one laboratory based test and two point of care tests.

thoracic pain can be caused by a myocardial infarction. the diagnosis of a myocardial infarction can be made by an ecg (st-elevation myocardial infarction, stemi). however, some myocardial infarctions can also occur without st-elevations on the ecg (non-st-elevation myocardial infarction, non-stemi). in the latter case, a quick acquisition of blood troponin levels is necessary to coin the diagnosis and initiate treatment. therefore, the investigators prospectively want to compare 3 clinical tests for measuring blood troponin levels in patients presenting to the emergency room with thoracic pain probably related to a non-stemi with regard to the time necessary to obtain the test results. the 3 tests are: 1. a laboratory based test: roche cobas e 602 2. a point of care test: radiometer aqt 90 flex 3. a point of care test: philips minicare i-20 the measured timeframe is the time between venipuncture to the point the test results are known.

Eligibility criteria:
inclusion criteria: * thoracic pain exclusion criteria: * unable to give informed consent

Keywords: troponin point of care test myocardial infarction
cardiac computed tomography: characteristics of isolated left ventricular non-compaction

Conditions: Left Ventricular Noncompaction; Isolated Noncompaction of the Ventricular Myocardium

Summary: the diagnostic criteria for isolated left ventricular non-compaction cardiomyopathy (ivnc) have been well established for echocardiography and cardiac magnetic resonance, such validation is lacking for computed tomography (ct). such criteria are of great clinical relevance as a growing number of patients undergo a cardiac ct scan in daily clinical routine. the investigators aim to test the diagnostic accuracy of cardiac ct in distinguishing ivnc from lesser degrees of trabecular layering seen in potential differential diagnoses such as cardiomyopathies and left ventricular hypertrophy or dilation. the investigators hypothesize that echocardiographic diagnosed pathological trabeculation can be distinguished by determining the ratio of non-compacted to compacted myocardium on cardiac ct.


Eligibility criteria:
inclusion criteria: * established diagnosis of ivnc or differential diagnosis * age: men \> 30 years, women \> 50 years without menstruation for at least 2 month. * written informed consent to participate exclusion criteria: contraindication for cardiac ct * renal insufficiency (gfr \< 60ml/min) * known allergy to iodinated contrast agent * known hyperthyroidism * non-sinus rhythm * known premature ventricular or supraventricular beats * hypotension (systolic blood pressure \< 100mmhg) contraindication for cmr * implanted cardiac pacemaker or defibrillator * other implanted medical devices (e.g. implantable cardioverter-defibrillator) * claustrophobia * known premature ventricular or supraventricular beats * pregnancy * claustrophobia

Keywords: isolated left ventricular non-compaction cardiac computed tomography cardiac magnet resonance imaging echocardiography
evaluation of the sinus-venous stent for the treatment of iliofemoral venous occlusive disease

Conditions: Venous Vascular Diseases and Syndromes

Summary: post market clinical follow-up study about the sinus-venous stent. patients with venous iliofemoral occlusive disease are treated with the sinus-venous stent. this observational study will provide 1 year data about safety and efficacy.


Eligibility criteria:
inclusion criteria: 1. age at study entry is at least 18 years. 2. patient must sign the informed consent form prior to the index-procedure. 3. patient suffers from acute or chronic venous occlusive disease indicated to be treated with a venous stent. 4. target lesion is located in the femoral vein, common femoral vein, external iliac vein, or common iliac vein. exclusion criteria: 1. intolerance to anticoagulant medication. 2. contra-indication for prolonged anticoagulant treatment. 3. life expectancy less than 1 year. 4. target vessel has been stented before. 5. coagulopathy or known uncorrectable bleeding diathesis. 6. recent (\<1 year) pulmonary embolism. 7. pregnancy. 8. known hypersensitivity to nitinol and/or nickel. 9. known to be, or suspected of being unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history). 10. legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the study. 11. patients in custody by juridical order. 12. patients who do not agree to the transmission of their coded data within the liability of documentation and notification. 13. close affiliation with the investigational site: e.g. a close relative of the investigator or a possibly dependent person (e.g. employee or student of the investigational site).